Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

menin-MLL interaction inhibitor JNJ-75276617

An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; mixed-lineage leukemia 1; MLL1; myeloid/lymphoid leukemia; histone-lysine N-methyltransferase 2A; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, menin-MLL interaction inhibitor JNJ-75276617 inhibits the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of leukemic cells with either KMT2A alterations such as gene rearrangements (KMT2A-r), duplications, and amplification, or nucleophosmin 1 gene (NPM1) alterations. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:menin-KMT2A interaction inhibitor JNJ-75276617
Menin-MLL1 interaction inhibitor JNJ-75276617
Code name:JNJ 75276617
JNJ-75276617
JNJ75276617
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search